Gastroenterology

NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (NAFLD), is the most common group of conditions in which there is an excess fat accumulation in the liver in people who intake little or no alcohol. It has been affecting many people mostly in developed countries and is known as fatty liver. However, in the most severe cases, people may develop Non-Alcoholic Steatohepatitis (NASH) where the accumulation of fat leads to liver inflammation and serious cirrhosis. It is characterized by severe damage to liver tissues and prominent...